SERUM ANTI-OXLDL ANTIBODIES IN PATIENTS WITH ANGIOGRAPHICALLY CONFIRMED CORONARY ARTERY DISEASE

  • Katerina Tosheska-Trajkovska Department of Medical and Experimental Biochemistry, Department of Biochemistry, Faculty of Medicine , St. Cyril and Methodius University in Skopje, North Macedonia
  • Irena Kostovska Department of Medical and Experimental Biochemistry, Department of Biochemistry, Faculty of Medicine , St. Cyril and Methodius University in Skopje, North Macedonia
  • Melda Emin Department of Medical and Experimental Biochemistry, Department of Biochemistry, Faculty of Medicine , St. Cyril and Methodius University in Skopje, North Macedonia
  • Hristina Ampova Department of Medical and Experimental Biochemistry, Department of Biochemistry, Faculty of Medicine , St. Cyril and Methodius University in Skopje, North Macedonia
  • Nikola Manev University Clinic for Cardiology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Zan Zimbakov University Clinic for Cardiology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Coskun Kerala University Clinic for Neurology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Jasna Bogdanska Department of Medical and Experimental Biochemistry, Department of Biochemistry, Faculty of Medicine , St. Cyril and Methodius University in Skopje, North Macedonia
  • Sonja Topuzovska Department of Medical and Experimental Biochemistry, Department of Biochemistry, Faculty of Medicine , St. Cyril and Methodius University in Skopje, North Macedonia

Abstract

Cardiovascular disease (CVD) remains the leading cause of death worldwide. Oxidized low density lipoprotein (oxLDL) is believed to be central to the atherosclerotic cascade. Oxidative modification of LDL induces immunogenic epitopes in the LDL molecule, and the presence of antibodies against oxidized LDL (anti-oxLDL) has been demonstrated in human sera. Anti-oxLDL titer not only can predict a presence of atherosclerotic CAD but may also be a marker of plaque instability. The aim of this study was to measure the concentration of anti-oxLDL in patients with angiographically confirmed coronary artery disease (CAD). Ninety patients with coronary artery disease and 90 controls were included in the study. Patients were selected according to the positive result of coronary angiography. Total cholesterol, triglycerides, HDL-c and LDL-c were determined on Roche C311 Cobas Analyzer and OxLDLD and anti-oxLDL were determined with sandwich ELISA technique. We find significant difference between CAD patients and controls regarding OxLDL (p< 0.001). Serum anti OxLDL antibodies were correlated with LDL-c and we found significant correlation (p<0.05) in the CAD group. The regression model showed that the variables Age, BMI, DBP, SBP, Total cholesterol, HDL-c LDL-c and TG explained 30.39% of the variance from the variable anti-ox-LDL. Our results show that serum levels of ox LDL are associated with presence of CAD and with the lipid parameters.


Keywords: cardiovascul ar disease, coronary artery disease, anti oxLDL, LDL.

References

1. WHO. The top 10 causes of death. WHO. 2017.
2. Holvoet P. Stress in obesity and associated metabolic and cardiovascular disorders. Scientifica (Cairo). 2012;2012:205027.
3. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation 2019;139(10):e56-e528.
4. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983;52:223-61.
5. Steinberg D, Witztum JL. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol 2010;30(12):2311-6.
6. Van Dijk RA, Kolodgie F, Ravandi A, Leibundgut G, Hu PP, Prasad A, et al. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res 2012;53(12):2773-90.
7. Obermayer G, Afonyushkin T, Binder CJ. Oxidized low-density lipoprotein in inflammation-driven thrombosis. J Thromb Haemost 2018;16(3):418-4287.
8. Chen C, Khismatullin DB. Oxidized low-density lipoprotein contributes to atherogenesis via co-activation of macrophages and mast cells. PLoS One. 2015;10(3):e0123088.
9. Sandhu PK, Musaad SM, Remaley AT, Buehler SS, Strider S, Derzon JH, et al. Lipoprotein Biomarkers and Risk of Cardiovascular Disease: A Laboratory Medicine Best Practices (LMBP) Systematic Review. J Appl Lab Med. 2016;1(2):214-29.
10. Lehtimäki T, Lehtinen S, Solakivi T et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology 1999; 19(1): 23-27.
11. Tsimikas S, Willeit P, Willeit J, Santer P, Mayr M, Xu Q, et al. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol. 2012;60(21):2218-29.
12. Virella G. Virella I, Leman RB, Pryor MB, Lopes-Virella MF. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. International Journal of Clinical & Laboratory Research 1993; 23(2): 95–101
13. Chen Q, Reis SE, Kammerer C et al. Association of anti-oxidized LDL and candidate genes with severity of coronary stenosis in the women's ischemia syndrome evaluation study. Journal of Lipid Research 2011; 52(4), 801-7.
14. Erkkilä AT, Närvänen O, Lehto S, Uusitupa MIJ, Ylä-Herttuala S. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2000; 20(1), 204–9.
15. Inoue T, Uchida T, Kamishirado H, Takayanagi K, Hayashi T, Morooka S. Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease. Journal of the American College of Cardiology 2001; 37(3), 775–9.
16. Laczik R, Szodoray P, Veres K et al. Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome. Lupus 2011;20(7), 730–5.
17. Tsimikas S, Brilakis ES, Lennon RJ et al. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. Journal of Lipid Research 2007, 48(2), 425–433.
18. Rossi GP, Cesari M, De Toni R et al. Antibodies to oxidized low-density lipoproteins and angiographically assessed coronary artery disease in white patients. Circulation 2003;108 (20), 2467–72.
19. Che J, G. Li, W. Wang et al. Serum autoantibodies against human oxidized low-density lipoproteins are inversely associated with severity of coronary stenotic lesions calculated by Gensini score. Cardiology Journal 2011;18(4), 364–370.
Published
2023-12-27
How to Cite
TOSHESKA-TRAJKOVSKA, Katerina et al. SERUM ANTI-OXLDL ANTIBODIES IN PATIENTS WITH ANGIOGRAPHICALLY CONFIRMED CORONARY ARTERY DISEASE. Journal of Morphological Sciences, [S.l.], v. 6, n. 3, p. 140-147, dec. 2023. ISSN 2545-4706. Available at: <https://jms.mk/jms/article/view/vol6no3-18>. Date accessed: 20 july 2024.
Section
Articles